What is great is that some of the people still with Sangart today were with Bob at the Letterman Army Institute of Research. Literally decades of research has gone into developing what became MP4, which is Sangart’s platform product.
What Bob discovered was that you could replicate a low-volume setting for some of the properties of blood. As a result, Bob developed the MP4 molecule as an agent that could very effectively transmit gases into the body.
There are the two gases that Sangart is currently focusing on with MP4: oxygen and carbon monoxide.
The oxygenated compound (MP4OX) is designed to deliver oxygen in the capillaries, where red blood cells may not naturally reach, when the body is suffering from hemorrhagic shock. The carbon monoxide formulation (MP4CO) is designed to deliver therapeutic levels of carbon monoxide to patients with sickle cell anemia.
Q: How does this compare to standard care available today?
A: There is no real treatment right now for trauma-related ischemia. When patients suffer blood loss due to a traumatic event, they eventually get to a critical care setting. They get all sorts of fluids, including blood, as well as surgery, of course. If the lactic acid levels, which are routinely measured, show lactic acidosis, an indicator of a lack of oxygen, then they receive MP4OX, in a blind setting, as an addition to standard of care. We measure the resolution of lactic acidosis, which indicates the delivery of oxygen to the ischemic tissue. We also look at other endpoints, such as the ICU setting to see if they are spending less time in the hospital on ventilators, etc.
Our Phase IIb study is evaluating MP4OX plus standard of care in trauma patients, with lactic acidosis due to hemorrhagic shock. It’s running in about 50 sites in about 15 countries throughout the world.
Q: How do you balance the need to raise capital with everyday activities?
A: We have been insulated more than most from all that is going on in the last two to three years because our investors are very patient.
We are funded through to our next major milestone events. Those being the generation of the next rounds of clinical data from the PhIIb study for MP4OX and the PhIb study for MP4CO.
With positive data from our two clinical trials, we are confident of raising additional funding from existing or alternative investors.
Q: Where do the biggest opportunities lie?
A: Studies show that our MP4 products can potentially be safer and more effective as therapies for trauma and sickle cell disease. We have investors who are very patient and willing to continue investing in us given our strong clinical data. Finally, and very importantly, we are willing to do our development overseas rather than the U.S. should it serve MP4’s needs.
CHI-Advancing California biomedical research and innovation